Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Open access
Giralt, Sergio, Garderet, Laurent, Durie, Brian, Cook, Gordon, Gahrton, Gosta, Bruno, Benedetto, Hari, Paremesweran, Lokhorst, Henk, McCarthy, Phillip, Krishnan, Amrita, Sonneveld, Pieter, Goldschmidt, Harmut, Jagannath, Sundar, Barlogie, Bart, Mateos, Maria, Gimsing, Peter, Sezer, Orhan, Mikhael, Joseph, Lu, Jin, Dimopoulos, Meletios, Mazumder, Amitabha, Palumbo, Antonio, Abonour, Rafat, Anderson, Kenneth, Attal, Michel, Blade, Joan, Bird, Jenny, Cavo, Michele, Comenzo, Raymond, de la Rubia, Javier, Einsele, Hermann, Garcia-Sanz, Ramon, Hillengass, Jens, Holstein, Sarah, Johnsen, Hans Erik, Joshua, Douglas, Koehne, Guenther, Kumar, Shaji, Kyle, Robert, Leleu, Xavier, Lonial, Sagar, Ludwig, Heinz, Nahi, Hareth, Nooka, Anil, Orlowski, Robert, Rajkumar, Vincent, Reiman, Anthony, Richardson, Paul, Riva, Eloisa, San Miguel, Jesus, Turreson, Ingemar, Usmani, Saad, Vesole, David, Bensinger, William, Qazilbash, Muzaffer, Efebera, Yvonne, Mohty, Mohamed, Gasparreto, Christina, Gajewski, James, LeMaistre, Charles F., Bredeson, Chris, Moreau, Phillipe, Pasquini, Marcelo, Kroeger, Nicolaus, Stadtmauer, Edward · 2015 · Biology of Blood and Marrow Transplantation

Abstract

In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be performed to define the role of salvage autologous HCT in patients with MM relapsing after primary therapy comparing it to "best non-HCT" therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding allogeneic HCT, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be performed in the context of a clinical trial if possible; (3) The role of postallogeneic HCT maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in patients with MM relapsing after primary therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2015.09.016

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Giralt, S., Garderet, L., Durie, B., Cook, G., Gahrton, G., Bruno, B., Hari, P., Lokhorst, H., McCarthy, P., Krishnan, A., Sonneveld, P., Goldschmidt, H., Jagannath, S., Barlogie, B., Mateos, M., Gimsing, P., Sezer, O., Mikhael, J., Lu, J., Dimopoulos, M., Mazumder, A., Palumbo, A., Abonour, R., Anderson, K., Attal, M., Blade, J., Bird, J., Cavo, M., Comenzo, R., de la Rubia, J., Einsele, H., Garcia-Sanz, R., Hillengass, J., Holstein, S., Johnsen, H. E., Joshua, D., Koehne, G., Kumar, S., Kyle, R., Leleu, X., Lonial, S., Ludwig, H., Nahi, H., Nooka, A., Orlowski, R., Rajkumar, V., Reiman, A., Richardson, P., Riva, E., San Miguel, J., Turreson, I., Usmani, S., Vesole, D., Bensinger, W., Qazilbash, M., Efebera, Y., Mohty, M., Gasparreto, C., Gajewski, J., LeMaistre, C. F., Bredeson, C., Moreau, P., Pasquini, M., Kroeger, N., & Stadtmauer, E.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2015-12
Volume
21
Issue
12
Pages
2039-2051
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2153614907
Cited by
165
References
6
FWCI
14.25
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.